The schizophrenia market across the seven major markets of the US,
France, Germany, Italy, Spain, the UK, and Japan, is set to rise from
$6.4 billion in 2015 to $7.3 billion by 2025, registering a compound
annual growth rate of 1.4%, according to research and consulting firm
Global Data.
The company’s latest report states that major drivers of this modest
growth include the uptake of novel pipeline products that have been
designed to satisfy unmet needs in the disease and development of
long-acting injectable (LAI) formulations of atypical antipsychotics in
order to improve patient compliance, a notable unmet need.
While schizophrenia market growth will primarily be driven by the
arrival of late-stage pipeline products, such as Minerva’s MIN-101 and
Intra-Cellular Therapies’ ITI-007, both of which are directed towards
the treatment of negative symptoms associated with schizophrenia, these
symptoms will remain a significant unmet need in the space.
More story on…!!!